Pharmaceutical Technology® spoke with Christian Dowdeswell, managing director, Arcinova, a Quotient Sciences company, ahead of CPHI Frankfurt 2025 to find out what makes an end-to-end service provider beneficial to sponsor companies and how digital technologies are changing the industry.
Smaller biopharmaceutical companies that own the molecules in early clinical development and outsource most of their development and manufacturing operations, often have limited resources. Therefore having a single partner, offering end-to-end services reduces the complexity in managing multiple partners because you have a single point of contact across the continuum.
"...a single provider brings these key benefits: reduction in complexity, reduction in time and the reduction in the total cost of ownership."
Watch the interview on PharmTech to hear Christian Dowdeswell's thoughts on...
- How early development of drug products are enhanced by a CDMO that offers end-to-end services?
- What role artificial intelligence and digital technologies play in accelerating drug discovery and improving manufacturing efficiency, along with some unresolved barriers to their full adoption?
- How the sector is reimagining supply chains to protect against rising tariffs, geopolitical shocks, and global disruptions?
- What he is looking forward to most at CPHI Frankfurt this year?
Credit:
Pharmaceutical Technology®, Author: Susan Haigney